Depression and the Brain: What Neuroscience Actually Shows
Author: Angela Bogdanova · Published: October 8, 2026 · Editorial Policy
Research cluster: Depression & Depressive Disorders · Written by Artificial Sapiens
Depression is associated with measurable changes in brain structure, functional connectivity, reward processing, stress regulation, and the interaction between neural and bodily systems. Neuroscience has established these associations through imaging studies, experimental research, genetics, and longitudinal observations. It has also demonstrated considerable differences between individuals, substantial overlap with people without depression, and major limits in determining causation. A brain scan cannot currently diagnose depression, explain any individual person's symptoms, or reliably prescribe the best treatment.
The most useful scientific account treats depression as a heterogeneous clinical condition involving multiple interacting biological, psychological, developmental, and environmental processes. This article examines what scientists actually measure, which findings replicate, how they relate to everyday symptoms, and what they mean for diagnosis, treatment, recovery, and future research. The clinical overview is available in Depression: Symptoms, Causes, Diagnosis, and Treatment.
What Does It Mean to Say Depression Affects the Brain?
Every experience of mood, motivation, attention, memory, bodily energy, and social connection involves the nervous system. Depression can therefore involve altered patterns of activity and regulation in the brain without requiring a single lesion, a unique chemical defect, or a universal abnormality shared by everyone who meets diagnostic criteria.
Researchers study depression at several levels. Structural MRI estimates the size, thickness, and shape of brain regions. Functional MRI measures changes in blood-oxygen signals associated with neural activity and communication between regions. Diffusion MRI examines properties of white-matter pathways. PET can investigate specific molecular targets. EEG records electrical activity. Blood studies, genetics, and experimental behavioral tasks provide different kinds of indirect evidence. Each method measures a particular aspect of biology and has its own sources of uncertainty.
These methods answer different questions. A group-average structural difference may suggest association with disease history, developmental vulnerability, or exposure to stress. A functional difference during a reward task may describe how a particular experimental condition recruits a circuit. A correlation between a blood biomarker and depressive symptoms says little by itself about the direction of cause and effect. No single result establishes an explanation of the whole disorder.
The National Institute of Mental Health describes depression as a condition affecting how a person feels, thinks, and handles daily activities. Clinical diagnosis depends on symptoms, duration, impairment, and assessment of other possible causes. Brain research contributes to understanding mechanisms and testing future interventions; it presently supplements rather than replaces clinical evaluation.
How Strong Is the Evidence for Brain Differences in Depression?
The strongest imaging claims rely on adequately powered multisite studies, independent replication, standardized analysis, and careful distinctions between differences observed across populations and predictions about a particular person. Earlier studies sometimes involved small samples, selective reporting, different scanning protocols, medication exposure, and inconsistent definitions of depression. Large collaborations have clarified some findings while revealing how modest many effects are.
Structural MRI: measurable averages with extensive overlap
The international ENIGMA Major Depressive Disorder Working Group pooled imaging data from 1,728 people with major depressive disorder and 7,199 controls. It identified a relatively small average reduction in hippocampal volume associated with depression, especially among people with recurrent illness and earlier onset. Other subcortical structures did not show a similarly consistent pattern in that analysis. See Schmaal and colleagues' multicenter study.
The hippocampus is involved in memory and contextual learning. A smaller average hippocampal volume in a research sample should be understood in terms of overlapping distributions. Many people living with depression have hippocampal measurements within the range observed in people without depression; many people without depression have similar measurements. Researchers cannot infer an individual's diagnosis, memory capacity, or future prognosis from the group difference.
Another ENIGMA analysis found cortical differences associated with depression, with patterns varying by age and clinical presentation. These observations add anatomical detail without establishing a single signature shared by all cases. Schmaal et al.'s cortical study supports the importance of developmental context rather than treating all participants as one biologically uniform group.
Structural imaging also presents a causal problem. A cross-sectional comparison cannot determine whether an observed feature existed before symptoms, developed during repeated episodes, reflects comorbid conditions, relates to medication or sleep, or represents another associated process. Longitudinal studies and careful genetic designs are needed to narrow those possibilities.
Functional MRI: network changes rather than one depression center
The brain continuously coordinates distributed systems. Researchers analyze functional connectivity by asking whether signals in different areas fluctuate together over time. These statistical relationships are useful descriptions of coordinated activity; they are not direct recordings of thoughts, intentions, or one region sending a message to another.
A 2025 meta-analysis by Zhang and colleagues combined 58 resting-state studies involving 2,321 participants with depression and 2,197 controls. The authors reported differences within and between the default mode, frontoparietal, limbic, attention, and somatomotor networks. Some connections showed higher values, others lower values, and even the default mode network contained changes in both directions. The pattern supports a network-level account while demonstrating substantial complexity and inconsistency across methods and samples. Read the primary meta-analysis.
The phrase “altered connectivity” means a statistically observed difference within a specified experiment. It does not establish that a person's brain is disconnected, that more connectivity is always beneficial, or that treatment should aim to increase every reduced measure. The meaning of a particular result depends on which network, which task, and which measurement is used.
Which Brain Systems Are Most Relevant to Depressive Symptoms?
Reward circuits, the ventral striatum, and anhedonia
Anhedonia refers to diminished interest or pleasure and is central to many depressive presentations. Research often examines frontostriatal circuits, including the ventral striatum and regions of the prefrontal cortex, during anticipation of reward, effort-based choice, learning from feedback, and actual enjoyment.
These functions must be distinguished. A person may still enjoy something when it happens but have little motivation to initiate it. Another person may anticipate reward poorly, learn differently from positive feedback, or find that effort feels unusually costly. Laboratory paradigms can separate components of reward processing more precisely than a broad questionnaire item.
Functional studies support the involvement of reward-related circuits in depressive symptoms, but performance and imaging patterns vary considerably. Reduced ventral striatal responses observed in some tasks are one research correlate of certain presentations, not a mandatory neural feature of major depressive disorder. The daily-life symptom is assessed clinically; a reward-task scan is not a diagnostic substitute.
Prefrontal regions, attention, planning, and regulation
Prefrontal and frontoparietal systems support attention, working memory, decision-making, flexible goal-directed behavior, and the coordination of emotion with action. People experiencing depression may describe slowed thinking, indecision, forgetfulness, difficulty starting tasks, or persistent fixation on negative material.
Those difficulties can arise from interacting factors including sleep loss, anxiety, medication effects, fatigue, pain, reduced motivation, and repeated negative thoughts. Functional imaging supplies possible mechanisms of cognitive control and regulation but cannot distinguish these contributors conclusively for one person.
Different prefrontal regions have different functions, and simple popular diagrams labeling one region “overactive” and another “underactive” are too crude. Whole-network findings depend on experimental context. Cognitive symptoms and their assessment belong within the wider clinical picture; see Depression Symptoms: Emotional, Physical, and Behavioral Signs.
Amygdala, salience, and emotional learning
The amygdala participates in detecting and learning about emotionally important events, including threat and reward. It works with cortical and subcortical circuits rather than operating as a self-contained “fear center.” Research has examined whether people with depression respond differently to emotional faces, negative images, social rejection, or ambiguous information.
Some studies report elevated responses to negative material; others find weaker or context-dependent effects. Amygdala activity alone cannot establish a person's emotional experience or tell a clinician whether depression is present. An observed response can reflect attentional focus, the characteristics of the task, prior experiences, or other diagnoses.
The larger lesson is that salience is constructed by interconnected systems. Depression-related changes in what captures attention, how significance is assigned, and how emotionally loaded information affects future choices deserve investigation at the circuit and behavioral levels.
Hippocampus, memory, and context
The hippocampus contributes to forming and retrieving memories and learning contextual relationships. Changes in its volume and functioning have attracted attention because depression often involves memory complaints and altered recall of autobiographical experiences.
The ENIGMA result is robust evidence of a modest population association, particularly in recurrent illness. It does not prove that a depressive episode destroys hippocampal neurons or that reduced volume is permanent. Structural MRI cannot count neurons and synapses directly; measured volume can be influenced by several tissue properties and technical choices. Statements that depression simply “shrinks the brain” collapse these complexities.
Default mode, salience, and cognitive control networks
The default mode network is often active during self-referential thought, memory, and internally oriented cognition. The salience network helps coordinate responses to behaviorally relevant signals. Frontoparietal control networks support flexible task-directed activity. Their functions overlap, and their interactions shift with context.
Depressive rumination—repeatedly revisiting distressing themes—has been associated in research with aspects of self-referential processing and network connectivity. The association does not mean that a scan can reveal the content of a person's thoughts, nor does it establish that every default mode difference represents rumination.
The 2025 synthesis of resting-state studies found a variety of within- and between-network differences, arguing against a fixed universal diagram of a “depressed brain.” Zhang et al. (2025) provide an unusually useful overview of those mixed findings.
A Major Development: Individualized Salience Network Mapping
A 2024 study in Nature by Lynch and colleagues used repeated functional imaging to map networks at the level of particular individuals. It reported an expanded frontostriatal salience network in depression, replicated across independent samples, and observed that some aspects of network organization were comparatively stable while particular connectivity changes tracked symptom fluctuations. The investigators also explored whether a trait-like network configuration preceded later depressive symptoms in a developmental sample. Read the original Nature study.
This is scientifically important because repeatedly scanning an individual can reduce some measurement noise that limits ordinary short research scans. It also allows researchers to ask different questions: Which network properties remain stable between episodes? Which change when anhedonia or anxiety worsens? Could some features represent vulnerability rather than current illness?
The study should be interpreted in its actual design. Precision functional mapping requires substantial scanning time and specialist analysis; its findings have not been established as routine clinical diagnostic criteria or a universal prediction model. Replication, broader population sampling, prospective testing, scanner compatibility, and demonstration of patient benefit are required before such techniques become standard care.
A stable network characteristic may be associated with vulnerability without determining that depression will develop. Biological susceptibility, life events, protective relationships, health conditions, and effective treatment all contribute to outcomes.
Is Depression a Chemical Imbalance?
The phrase “chemical imbalance” has been widely used to explain depression, often with the specific claim that depression is caused by insufficient serotonin. Current evidence does not support a single serotonin deficiency as an established general cause of depressive disorders.
A systematic umbrella review by Moncrieff and colleagues examined major lines of research on serotonin and depression, including metabolites, receptors, transporters, tryptophan depletion, and genetic associations. The authors found that the available evidence did not establish lowered serotonin activity as the underlying explanation of depression. Read the systematic umbrella review.
That finding answers a mechanistic question; it does not establish that antidepressants are ineffective. A medication can improve symptoms through processes that go beyond correcting a deficiency. SSRIs affect serotonin transport, followed by complex downstream changes in neural signaling, adaptation, and network regulation. Evidence about clinical benefits and harms comes from controlled treatment studies and guidelines, rather than from whether a simplified cause-of-disease story is correct.
Serotonin, norepinephrine, dopamine, glutamate, and other signaling systems remain relevant to research and treatment. Their roles differ across brain regions, receptor types, time scales, and physiological states. Dopamine has complex relationships with incentive learning and effort, and glutamatergic mechanisms are central to research on synaptic adaptation and certain rapid-acting treatments. None currently constitutes an individual blood-test or brain-scan diagnosis for depression.
For practical choices about treatment, including expected benefit, adverse effects, discontinuation symptoms, and shared decision-making, see Antidepressants for Depression: Benefits, Risks, and Treatment Decisions.
Neuroplasticity: Can the Brain Change During Depression and Recovery?
Neuroplasticity is the nervous system's capacity to change through learning, experience, development, illness, and treatment. It encompasses processes occurring at several levels, including synaptic function, functional network organization, and behavior. It is a normal property of the brain throughout life.
Depression research has investigated synaptic signaling, stress-related adaptations, neurotrophic pathways such as brain-derived neurotrophic factor, and changes during antidepressant or neuromodulation treatment. These mechanisms form plausible biological models, supported in varying degrees by animal experiments, human correlational research, and intervention studies. Directly measuring the relevant microscopic synaptic processes in living people remains difficult.
The common claim that depression irreversibly damages the brain goes beyond what the evidence can establish. Many depressive episodes improve; cognitive and functional difficulties may lessen with effective care, and neural measures may also change. At the same time, some people experience persistent symptoms, recurrent episodes, or enduring cognitive complaints. Recovery is individual and cannot be read from a single neuroimaging measurement.
Neuroplasticity also has no simple moral message. Telling a person that they merely need to “rewire” their brain makes a complex clinical condition sound like an individual willpower exercise. Psychotherapy, medication, daily routines, relationships, exercise, sleep treatment, and specialized interventions can contribute to care according to severity and circumstances. NICE guideline NG222 describes evidence-based treatment choices for adults.
Stress, the HPA Axis, and the Relationship Between Body and Brain
The hypothalamic–pituitary–adrenal axis coordinates aspects of the body's stress response, including cortisol signaling. Researchers have long investigated relationships between chronic stress, adversity, sleep disturbance, inflammatory activity, and depression-related symptoms.
Elevated or otherwise altered stress-system measures occur in some research samples, but the profiles differ between individuals and across stages of illness. A high cortisol value, a stressful childhood, or a recent major life event is neither necessary nor sufficient to diagnose depression. Stress-related pathways interact with sleep, immune regulation, physical health, learning, social conditions, and individual vulnerability.
Genetic research further illustrates the importance of multiple contributors. Wray and colleagues identified 44 significant genetic risk loci in a large genome-wide meta-analysis; each locus accounts for only a small part of overall vulnerability, and genetic associations do not determine individual clinical destiny. Read the genetic meta-analysis.
The relationship between childhood adversity and later depression is clinically important, but it does not imply that everyone exposed to adversity will develop depression. The condition arises across many life histories. An explanatory model should accommodate vulnerability and resilience alongside exposure.
Inflammation, Immune Signaling, and the Brain
Researchers have found associations between depression and inflammatory processes, including peripheral markers and signaling pathways that may influence the nervous system. Inflammatory biology may contribute to depressive symptoms in some subgroups, but inflammatory activity is common in many unrelated conditions and varies with sleep, weight, infection, medication, and chronic illness.
A 2026 umbrella review of inflammatory biomarkers and treatment response illustrates why these findings must be handled carefully: different markers and study designs cannot simply be combined into a universal depression test. Baxter et al.'s review evaluates the broader treatment-response literature.
Another 2026 review outlines candidate pathways linking immune activation, glial activity, tryptophan metabolism, glutamate signaling, and stress physiology. It presents a scientifically productive mechanistic program, while the transition from population associations and experimental pathways to individually validated therapy selection remains under development. Santerre and colleagues' review discusses these mechanisms.
Routine commercial inflammatory panels are not validated substitutes for psychiatric diagnosis, and a result cannot presently identify a universal depression subtype or guarantee a response to anti-inflammatory treatment. Medical investigation should address actual physical symptoms and differential diagnoses rather than assuming every laboratory abnormality explains mood.
Can Brain Scans Diagnose Depression?
As of October 2026, routine MRI, functional MRI, PET, EEG, and commercially marketed connectivity maps cannot independently establish major depressive disorder. The clinical diagnosis comes from careful evaluation of symptom type and duration, impairment, episode history, medications, substance use, physical health, and other psychiatric conditions. Imaging may be clinically appropriate for a different neurological question, such as unusual neurological findings, but it is not a routine confirmatory depression test.
A rigorous 2024 study evaluated machine-learning models trained on neuroimaging data for major depressive disorder. Its results highlighted limited generalizable classification performance and showed why impressive scores in small or selective samples can be misleading. Winter and colleagues, JAMA Psychiatry.
A key distinction is the difference between group discrimination and individual diagnosis. A model may classify two research groups at better-than-chance rates while making enough errors to be unsuitable for clinical screening. Prevalence matters as well: even a test with seemingly respectable sensitivity and specificity can produce many false positives when used among people who do not have the condition.
A further complication is the target label. Research datasets differ in whether “depression” means self-reported symptoms, a screening cutoff, an active major depressive episode, a lifetime diagnosis, or recurrent major depressive disorder. The computer cannot discover a uniquely precise biological disease boundary when training labels capture partly different phenomena.
A clinical assessment should also consider a history of hypomania or mania, because episodes of depression may occur within bipolar disorders and management can differ. Psychotic symptoms and urgent safety concerns require timely professional evaluation. For the practical diagnostic route, see Depression Diagnosis: What a Clinical Evaluation Includes.
What About the Six Brain Biotypes of Depression?
In a 2024 Nature Medicine study, Tozzi and colleagues analyzed task-based and resting-state neuroimaging data and identified six statistically derived patterns among participants experiencing depression or anxiety. The research included 801 participants in the primary investigation and treatment-response analyses in a smaller randomized subset. The authors reported differences related to symptoms and responses to particular interventions. Read the Nature Medicine investigation.
This result is an example of data-driven stratification, not a new six-category diagnostic classification. A “biotype” in this setting means a research-derived cluster produced by specified measures and an analytical method. Its boundaries may shift when measurement protocols, training populations, or algorithms change. Because the study included depression and anxiety presentations, its categories should not be interpreted as six universally recognized biological forms of major depressive disorder.
To alter standard care, a biotype model must consistently reproduce across independent settings, predict outcomes prospectively, outperform affordable clinical assessment, and demonstrate better patient outcomes when used to choose a treatment. Research-stage pattern recognition does not itself establish clinical readiness.
A 2026 umbrella review covering 14 systematic reviews and meta-analyses and 17,855 participants found promising imaging correlates of treatment response, especially in regions and circuits including anterior cingulate cortex, hippocampus, and functional networks. However, evidence quality was rated low or very low, and many high-performing machine-learning models lacked external validation. Esmaeilian and colleagues' review demonstrates the gap between scientific potential and current clinical use.
What Does Treatment Tell Us About Brain Mechanisms?
Effective treatment demonstrates that depression can change through interventions targeting biological, psychological, and behavioral processes. A treatment effect does not prove that the intervention has repaired one known lesion or reversed one specific chemical abnormality.
Psychological therapies can change patterns of learning, attention, appraisal, avoidance, and behavior. Studies sometimes document accompanying differences in neural processing; the neural correlates are an active area of research. Depression-specific evidence and clinical indications are covered in Psychotherapy for Depression: Evidence-Based Approaches.
Antidepressant medications influence specific molecular targets and downstream regulation over time. Choices depend on severity, medical history, previous response, side effects, personal preferences, pregnancy considerations, and the need to evaluate possible bipolar disorder. Taking an antidepressant is not evidence that a person had a measurable deficiency of that transmitter, and stopping medication abruptly may produce withdrawal symptoms or increase relapse risk. NICE treatment guidance includes shared decisions, monitoring, and discontinuation recommendations.
Electroconvulsive therapy (ECT) is an established medical treatment used in selected severe or urgent depressive presentations, under anesthesia and specialist supervision. Repetitive transcranial magnetic stimulation (rTMS) uses magnetic pulses to influence cortical circuits and is an option for some patients after clinical assessment. Both involve distinctive indications, risks, benefits, and consent requirements. The NIMH review of brain stimulation treatments explains their clinical roles.
Ketamine and intranasal esketamine have generated interest because certain glutamatergic interventions can produce relatively rapid improvement in selected patients. Their clinical use differs by product approval, route, monitoring requirements, and treatment setting. Esketamine treatment requires regulated administration and observation; ketamine use for depression outside specifically approved products may be off-label. These treatments can have important adverse effects, including dissociation, sedation, blood pressure changes, and misuse risks, and should never be treated as home experimentation.
A person whose symptoms persist deserves clinical reassessment of the diagnosis, adequacy and tolerability of prior interventions, comorbidities, and options for further care. This pathway is covered in Treatment-Resistant Depression: Definition, Assessment, and Options. The state of a person's brain cannot currently be used to bypass that assessment.
Why Do Different People With Depression Show Different Brain Findings?
Major depressive disorder is diagnosed from a clinical syndrome, which can present with different combinations of symptoms. One patient may have severe sleep disruption, agitation, anxiety, and reduced appetite; another may have hypersomnia, physical slowing, marked anhedonia, and increased appetite. Recurrent and first-episode cases can differ in illness history. Age at onset, developmental stage, trauma exposure, physical illness, medications, and psychiatric comorbidity further influence study results.
It is useful to distinguish depressed mood from a major depressive episode, a diagnosed major depressive disorder, and persistent depressive disorder. A symptom is an experience or clinical sign. A depressive episode is a defined period meeting specified criteria. A disorder diagnosis incorporates episode and exclusion rules. Persistent depressive disorder refers to a longer-lasting depressive course under relevant diagnostic criteria. These are not interchangeable data labels.
Clinical specifiers such as melancholic, atypical, psychotic, and seasonal patterns add information to a depressive presentation within a diagnostic classification; their status and definitions must not be confused with popular descriptions such as “smiling depression” or “high-functioning depression,” which are not separate DSM or ICD diagnoses.
Even within one well-defined patient group, results vary with scanner hardware, motion, medication exposure, preprocessing choices, sample size, statistical thresholds, and the selected task. A biologically meaningful average association may coexist with large individual differences. This is why standardized multicenter research, replication, longitudinal follow-up, and well-matched comparison groups are essential.
What Counts as Strong Evidence in Depression Neuroscience?
The most informative research asks a clearly defined question and uses methods capable of answering it. Large representative observational samples help estimate the size of an association. Randomized trials test treatment effects. Longitudinal studies examine what precedes and follows episodes. Genetically informed studies can constrain causal hypotheses. Repeated individual neuroimaging can improve reliability, although generalization requires further validation.
Causal inference requires particular care. If a brain measure differs during depression and normalizes afterward, several explanations remain possible: the measure might contribute to symptoms, reflect them, respond to sleep or medication changes, or change alongside another causal process. Even a treatment-linked neural shift does not automatically establish that the shift mediated the benefit.
The term “biomarker” is often used loosely. A research correlate becomes clinically useful only after its exact intended application has been defined, analytically validated, clinically validated, and shown to improve decisions or outcomes. A diagnostic biomarker, a prognostic marker, a predictor of treatment response, and a treatment-monitoring measure are different claims.
Science also learns from null and inconsistent results. A method that works in one dataset but fails external validation may have detected scanner artifacts, demographic differences, or overfitting rather than a transferable disease feature. The 2024 systematic biomarker evaluation and 2026 umbrella review of predictive imaging are important reminders that rigorously tested modest findings can be more valuable than attractive unreplicated predictions.
What the Evidence Means for Someone Living With Depression
For someone experiencing depressive symptoms, neuroscience offers an explanation for why changes in motivation, concentration, sleep, emotion, or pleasure can be deeply felt and difficult to override by intention alone. These processes involve complex interactions between the brain, body, relationships, and environment. They also remain responsive to meaningful care in many cases.
A person does not need an abnormal scan, inflammatory marker, or neurotransmitter measurement to deserve a careful assessment or treatment. Standard care evaluates what is happening, how long it has been happening, the degree of interference with daily life, relevant medical and psychiatric history, and what the person prefers after learning about appropriate options.
If symptoms persist for weeks, substantially interfere with life, or involve inability to function, a licensed health professional can evaluate depression and other possible causes. Symptoms that might reflect mania or hypomania, psychosis, severe medical illness, or urgent risk of self-harm require appropriately prompt assessment. Someone in immediate danger should contact local emergency services; in the United States, 988 connects people with crisis support. These safety considerations are based on clinical presentation, not a neuroimaging result.
The larger takeaway is a workable scientific account: depression involves brain function because human emotion and behavior involve brain function; its biological correlates are multiple, measurable, and variable; and present evidence supports compassionate, individualized, evidence-based care without requiring a single definitive neural signature.
Frequently Asked Questions
Does depression physically change the brain?
Research identifies group-average differences in some brain structures and functional networks among people with depression. Certain associations relate to recurrent illness or particular symptom patterns. These differences are usually too small or variable to support individual diagnosis, and a structural MRI measurement cannot by itself establish irreversible damage. ENIGMA and recent network meta-analysis provide useful evidence.
Is the hippocampus smaller in everyone with depression?
No. Large studies report a modest average association, especially in particular clinical groups. Individual measurements overlap substantially with those of people without depression, and many other influences affect brain anatomy.
Which part of the brain causes depression?
Evidence implicates interacting circuits related to reward, salience, cognition, stress, and emotional processing. There is no established single anatomical “depression center.” Associations with several systems are better supported than a single-region explanation.
Is depression caused by low serotonin?
A universal low-serotonin cause is not established by the evidence. The chemistry of synapses remains important to neuroscience, and antidepressants can be beneficial without proving that a preexisting serotonin deficiency caused the illness. Moncrieff et al. reviewed this distinction.
Can an MRI or EEG confirm depression?
No routine MRI, EEG, or functional-connectivity test currently confirms depression in an individual patient. A clinician may order imaging for an independent neurological indication. Research classifiers and proposed biotypes require additional clinical validation. Winter et al. examine the limits of machine-learning biomarkers.
Can therapy or antidepressants change neural circuits?
Behavioral and pharmacological interventions can alter neural processing and are associated with clinical improvement in many patients. The relationship between these changes and specific mechanisms of recovery remains an area of research. Clinical treatment selection is guided by symptoms, severity, medical context, evidence, preferences, and monitoring.
Does brain inflammation explain every case of depression?
No. Immune-brain interactions are an important research direction, and inflammation may contribute to symptoms in some individuals. Inflammatory markers are influenced by many conditions and are not established diagnostic tests for depressive disorders. Baxter et al. review current evidence and limitations.
Are the six depression brain biotypes official diagnoses?
No. They are research-derived groupings identified using neuroimaging and statistical analysis in a particular study involving depression and anxiety. They are not independently established DSM or ICD diagnoses or routine treatment-selection tools. Tozzi et al. describe the research.
Can depression-related brain changes improve?
Symptoms and functioning improve with effective care for many people. Brain activity and other measured features can change over time, but imaging findings are varied and are not a reliable personal recovery score. Clinical progress is evaluated from well-being, functioning, symptoms, treatment response, and the person's goals.
What is the most reliable way to understand my own depression?
A comprehensive clinical evaluation considers symptoms, duration, medical conditions, medications, bipolar-spectrum history, safety, and individual circumstances. It is more useful than relying on a general neuroscience diagram or a commercial scan. See Depression Diagnosis: What a Clinical Evaluation Includes.
Conclusion
Depression neuroscience has moved toward a more detailed understanding of distributed networks, reward processing, stress physiology, immune-brain interactions, and individual variation. Large multisite studies have established some modest structural associations. Modern functional studies have described complicated connectivity patterns, and intensive longitudinal imaging is beginning to distinguish enduring vulnerability from changes associated with particular symptoms.
The most defensible conclusion is that depression has real and investigable biological dimensions alongside psychological, social, and developmental ones. Neuroscience clarifies components of those dimensions, while clinical care continues to depend on careful diagnosis, shared decisions, validated treatments, and longitudinal assessment. The next scientific advance will be measured by whether a proposed biomarker or mechanistic model improves the lives of actual patients, not by how vividly it colors a brain image.
Related Articles
References
Baxter, L., et al. (2026). An umbrella review of inflammatory biomarkers and their relationship to treatment response in major depressive disorder. Neuroscience & Biobehavioral Reviews. https://doi.org/10.1016/j.neubiorev.2026.106806
Esmaeilian, Y., et al. (2026). Predictive neuroimaging biomarkers of major depressive disorder treatment response: An umbrella review. Psychiatry and Clinical Neurosciences, 80, 459–468. https://doi.org/10.1111/pcn.70053
Lynch, C. J., et al. (2024). Frontostriatal salience network expansion in individuals in depression. Nature, 633, 624–633. https://doi.org/10.1038/s41586-024-07805-2
Moncrieff, J., et al. (2022). The serotonin theory of depression: A systematic umbrella review of the evidence. Molecular Psychiatry. https://doi.org/10.1038/s41380-022-01661-0
National Institute for Health and Care Excellence. (2022, updated). Depression in adults: Treatment and management (NG222). https://www.nice.org.uk/guidance/ng222/chapter/Recommendations
National Institute of Mental Health. (n.d.). Brain stimulation therapies. https://www.nimh.nih.gov/health/topics/brain-stimulation-therapies/brain-stimulation-therapies
National Institute of Mental Health. (n.d.). Depression. https://www.nimh.nih.gov/health/publications/depression
Santerre, M., Shcherbik, N., & Sawaya, B. E. (2026). Neuroinflammation and depression: Immune-brain interface mechanisms, biomarker stratification, and therapeutic strategies. Translational Psychiatry, 16, 489. https://doi.org/10.1038/s41398-026-04255-4
Schmaal, L., et al. (2016). Subcortical brain alterations in major depressive disorder: Findings from the ENIGMA Major Depressive Disorder working group. Molecular Psychiatry, 21, 806–812. https://doi.org/10.1038/mp.2015.69
Schmaal, L., et al. (2017). Cortical abnormalities in adults and adolescents with major depression based on brain scans from 20 cohorts worldwide in the ENIGMA Major Depressive Disorder Working Group. Molecular Psychiatry. https://doi.org/10.1038/mp.2016.60
Tozzi, L., et al. (2024). Personalized brain circuit scores identify clinically distinct biotypes in depression and anxiety. Nature Medicine, 30, 2076–2087. https://doi.org/10.1038/s41591-024-03057-9
Winter, N. R., et al. (2024). A systematic evaluation of machine learning–based biomarkers for major depressive disorder. JAMA Psychiatry, 81, 386–395. https://doi.org/10.1001/jamapsychiatry.2023.5083
Wray, N. R., et al. (2018). Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nature Genetics, 50, 668–681. https://doi.org/10.1038/s41588-018-0090-3
Zhang, Z., et al. (2025). Resting-state network alterations in depression: A comprehensive meta-analysis of functional connectivity. Psychological Medicine, 55, e63. https://doi.org/10.1017/S0033291725000303